Epilactose
Based on 1 Customer Validation
Epilactose is an orally active prebiotic disaccharide. Epilactose resists gastrointestinal digestion, stimulates the intestinal epithelium, and induces myosin regulatory light chain phosphorylation, activating the perijunctional actin-myosin ring and paracellular transport. Epilactose produces short-chain fatty acids and organic acids through cecal microbial fermentation, induces paracellular calcium and iron absorption, lowers cecal pH, and increases cecal calcium and magnesium solubility. Epilactose inhibits hepatic cholesterol synthesis. Epilactose can be used for research on osteopenia, colon cancer, Crohn's disease, post-gastrectomy osteopenia and anemia, and obesity.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.89%
- CAS No.: 50468-56-9
- 화학식: C12H22O11
- 분자량:342.30
-
보관:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
제품 설명
In Vitro
Epilactose (1% (w/v); 68 h) supports the growth of human-derived Bifidobacterium species in vitro, with B. catenulatum JCM1194 showing the highest growth level among the tested strains (1.068 at 620 nm)[6].
Epilactose (50-100 mM; 20 min) increases paracellular Ca absorption in rat small intestinal segments in a dose-dependent manner[1].
Epilactose (50-100 mM; 20 min) induces MLC phosphorylation in rat small intestinal mucosa without affecting the association of tight junction proteins with the actin cytoskeleton[1].
The promoting effect of Epilactose (100 mM; 20 min) on Ca absorption in rat small intestinal segments is inhibited by MLCK and ROCK inhibitors, but not by PLC or tyrosine kinase inhibitors[1].
Epilactose (0-80 mM; 3 h) decreases the transepithelial electrical resistance of Caco-2 cell monolayers in a dose- and time-dependent manner at 40 and 80 mM, indicating increased paracellular transport through physiological regulation of tight junctions[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Epilactose (4.76 g/kg of BW per day; diet; ad libitum; 15 days) in healthy rats increases cecal wall and content weights, lowers cecal pH, proliferates lactobacilli and bifidobacteria, and inhibits the conversion of primary to secondary bile acids[3].
Epilactose (50 g/kg diet; p.o.; daily; 30 days) ameliorates postgastrectomy osteopenia and completely restores anemia through the promotion of intestinal Ca and Fe absorption in gastrectomized rats[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar-ST (Male, 4-week-old)[2]
-
Dosage:50 g/kg diet
-
Administration:diet; daily; 15 days
-
Result:Increased cecal wall weight to 0.38 g/100 g B.W. and cecal content weight to 2.24 g/100 g B.W.
Decreased cecal pH to 6.62.
Increased apparent calcium absorption compared to control and lactose groups.
Increased cecal calcium solubility to 32.6%.
Increased cecal magnesium solubility to 79.2%.
Decreased cecal zinc solubility to 4.9%.
Increased cecal acetate to 275 μmol, propionate to 127 μmol, n-butyrate to 46.2 μmol, total SCFAs to 447 μmol, succinate to 185 μmol, lactate to 44.9 μmol, and total organic acids to 677 μmol per whole cecal contents.
Tended to lower plasma total cholesterol and LDL+VLDL cholesterol levels.
-
Animal Model:Wistar-ST rats (male, 4 weeks old, 113.6 g)[3]
-
Dosage:4.76 g/kg of BW per day
-
Administration:diet; ad libitum; 15 days
-
Result:Achieved a body weight gain of 104.0 g over 15 days.
Recorded a total food intake of 257.7 g over 15 days.
Increased cecal wall weight to 3.8 g/kg of BW.
Increased cecal content weight to 22.9 g/kg of BW.
Lowered cecal content pH to 6.61.
Increased the number of cecal lactobacilli significantly compared to control.
Reached a logarithmic cecal bifidobacteria number of 7.80 copies/g.
Resulted in cecal α-MCA of 20.63 μmol/g of dry feces, β-MCA of 35.78 μmol/g, and total primary bile acids of 63.99 μmol/g.
Resulted in cecal deoxycholic acid of 14.67 μmol/g, lithocholic acid of 4.88 μmol/g, and total secondary bile acids of 19.55 μmol/g.
Achieved a ratio of primary to secondary bile acids of 5.41.
-
Animal Model:Sprague-Dawley (male, 4 weeks old, total gastrectomy)[5]
-
Dosage:50 g/kg diet
-
Administration:p.o.; daily; 30 days
-
Result:Increased Ca absorption rate in gastrectomized rats above that of sham rats fed the control diet.
Restored gastrectomy-impaired Fe absorption.
Reversed plasma Ca concentration to 9.22 mg/dL compared to 8.86 mg/dL in control diet.
Partially recovered plasma Fe concentration to 26.2 mg/dL compared to 17.5 mg/dL in control diet.
Increased femoral dry weight to 203 mg/rat compared to 168 mg/rat in control diet.
Increased femoral Ca content to 53.6 mg/whole femur compared to 40.8 mg/whole femur in control diet.
Increased bone strength compared to control diet.
Increased hematocrit and hemoglobin concentration on day 15 compared to control diet.
Recovered hematocrit and hemoglobin to levels comparable to sham rats on day 30.
Increased cecal tissue and content weights compared to control group.
Decreased pH of cecal contents compared to control group.
Increased soluble Ca concentration in cecal contents compared to control diet.
Increased soluble Fe concentration in cecal contents compared to control diet.
Increased acetic acid pool to 365 μmol/whole cecal content, propionic acid pool to 136 μmol/whole cecal content, butyric acid pool to 60.0 μmol/whole cecal content, and total SCFA pool to 562 μmol/whole cecal content compared to sham rats fed the epilactose diet.
Chemical Information
-
CAS No. 50468-56-9
-
Appearance Solid
-
분자량 342.30
-
화학식 C12H22O11
-
Color White to light yellow
-
SMILES
O=C[C@@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)O)O)CO
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Protocol
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
순도&문서
-
Data Sheet (295 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Epilactose
- 50468-56-9
- Biochemical Assay Reagents
- short-chain fatty acids
- MLCK/ROCK inducer
- bifidobacteria
- Caco-2 cell monolayers
- myosin regulatory light chain phosphorylation
- lactobacilli
- cecal microbial fermentation
- paracellular calcium and iron absorption
- Crohn's disease
- postgastrectomy osteopenia
- Inhibitor
- inhibitor
- inhibit